| EPB0141 | Prevalence and associated risk factors of hepatotoxicity on tuberculosis prevention therapy in a Thai HIV cohort | E-poster | Co-infections (including opportunistic infections) |
| EPB0142 | High prevalence of asymptomatic Sexually Transmitted Infections in men patients living with HIV | E-poster | Co-infections (including opportunistic infections) |
| EPB0143 | Cryptococcal antigen (CrAg) screening a need of the hour for PLHIV of Eastern India | E-poster | Co-infections (including opportunistic infections) |
| EPB0144 | Differences in time to HCV treatment initiation following HCV diagnosis in the broad direct-acting antiviral era in five countries | E-poster | Co-infections (including opportunistic infections) |
| EPB0145 | The epidemiological profile of mpox cases in Rio de Janeiro, Brazil: changes over time during the 2022 outbreak | E-poster | Co-infections (including opportunistic infections) |
| EPB0146 | Clinical characteristics and outcome of toxoplasma encephalitis in HIV patients from Indonesian tertiary referral hospital | E-poster | Co-infections (including opportunistic infections) |
| EPB0147 | Efficacy and safety of different regimens in the treatment of HIV patients with latent tuberculosis infection: a systematic review and network meta-analysis of randomized controlled trials | E-poster | Co-infections (including opportunistic infections) |
| EPB0148 | CMV co-infection and HIV disease control among children living with HIV in Canada | E-poster | Co-infections (including opportunistic infections) |
| EPB0149 | Integration of HCV treatment at district antiretroviral therapy clinics during COVID-19 pandemic: a success story from Viet Nam | E-poster | Co-infections (including opportunistic infections) |
| EPB0150 | 24 week efficacy and safety of efavirenz- and dolutegravir-based antiretroviral therapy with isoniazid and rifapentine for tuberculosis preventive therapy (1HP and 3HP) in Thai people living with HIV | E-poster | Co-infections (including opportunistic infections) |